Early Signs Monitoring Through a Period of Relapse in a Highly Symptomatic Chronic Schizophrenic Patient

1994 ◽  
Vol 22 (2) ◽  
pp. 147-152
Author(s):  
Charles King ◽  
Geoff Shepherd

The Early Signs Scale (Birchwood et al., 1989) for the monitoring of prodromal symptoms was used with a schizophrenic inpatient with severe residual psychotic symptoms. Marked changes in the scores were obtained in both self and observer reports during a period in which the patient was considered to “relapse”. The results suggest the possible wider applicability of the Early Signs Scale to patients who experience severe residual symptoms between relapse episodes.

1959 ◽  
Vol 105 (441) ◽  
pp. 1112-1118
Author(s):  
G. A. Dransfield ◽  
M. W. Browne

Recent work, such as that of Moore and Martin (1957), has shown that reserpine is of value in the treatment of the chronic schizophrenic patient. Attention has however been drawn to the incidence of side-effects in this form of treatment. These side-effects have limited the application of the drug and have also led to the search for a related substance, of similar clinical effect but without the troublesome toxic effects. This present trial is of a substance, deserpidine (Harmonyl, Abbott Laboratories), which it was thought would fulfil these requirements. The isolation of this alkaloid was first reported in 1955 by Stoll and Hofman, and it has subsequently been identified as 11-desmethoxy-reserpine (Harrisson, 1955) which can be represented thus:


Psychiatry ◽  
1984 ◽  
Vol 47 (4) ◽  
pp. 324-332 ◽  
Author(s):  
Michael A. Selzer ◽  
Monica Carsky ◽  
Bruce Gilbert ◽  
William Weiss ◽  
Matthew Klein ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document